SG10201505785QA - Binding proteins for hepcidin - Google Patents

Binding proteins for hepcidin

Info

Publication number
SG10201505785QA
SG10201505785QA SG10201505785QA SG10201505785QA SG10201505785QA SG 10201505785Q A SG10201505785Q A SG 10201505785QA SG 10201505785Q A SG10201505785Q A SG 10201505785QA SG 10201505785Q A SG10201505785Q A SG 10201505785QA SG 10201505785Q A SG10201505785Q A SG 10201505785QA
Authority
SG
Singapore
Prior art keywords
hepcidin
binding proteins
proteins
binding
Prior art date
Application number
SG10201505785QA
Inventor
Stefan Trentmann
Gabriele Matschiner
Arne Skerra
Andreas Hohlbaum
Martin Huelsmeyer
Hendrik Gille
Hans-Juergen Christian
Kristian Jensen
Aiba Rachida Siham Bel
Original Assignee
Pieris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Ag filed Critical Pieris Ag
Publication of SG10201505785QA publication Critical patent/SG10201505785QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation
SG10201505785QA 2010-08-16 2011-08-16 Binding proteins for hepcidin SG10201505785QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37419910P 2010-08-16 2010-08-16

Publications (1)

Publication Number Publication Date
SG10201505785QA true SG10201505785QA (en) 2015-09-29

Family

ID=44630372

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013008222A SG187695A1 (en) 2010-08-16 2011-08-16 Binding proteins for hepcidin
SG10201505785QA SG10201505785QA (en) 2010-08-16 2011-08-16 Binding proteins for hepcidin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013008222A SG187695A1 (en) 2010-08-16 2011-08-16 Binding proteins for hepcidin

Country Status (12)

Country Link
US (3) US9051382B2 (en)
EP (2) EP2606061B8 (en)
KR (2) KR101918024B1 (en)
CN (2) CN107082803A (en)
AU (1) AU2011290751B2 (en)
CA (1) CA2808392C (en)
DK (1) DK2606061T3 (en)
NZ (1) NZ606584A (en)
RU (1) RU2625011C2 (en)
SG (2) SG187695A1 (en)
WO (1) WO2012022742A1 (en)
ZA (1) ZA201300975B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006020710D1 (en) 2005-04-22 2011-04-28 Fred Hutchinson Cancer Res Foundation FLUORESCENT CHLOROTOXIN CONJUGATE AND METHOD FOR THE INTRAOPERATIVE VIEW OF CANCER
WO2009140599A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
RU2707126C2 (en) * 2009-12-07 2019-11-22 Пирис Аг Human lipolocal 2 malletes (lcn2, hngal) with affinity for specific target
EP2531206B1 (en) 2010-02-04 2017-05-31 Morphotek, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
JP2013532126A (en) 2010-05-11 2013-08-15 フレッド ハッチンソン キャンサー リサーチ センター Chlorotoxin variants, conjugates, and methods of using them
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
WO2012022742A1 (en) * 2010-08-16 2012-02-23 Pieris Ag Binding proteins for hepcidin
SG10201604574UA (en) 2011-12-12 2016-07-28 Pieris Ag Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
US9758554B2 (en) 2012-01-31 2017-09-12 Technische Universitaet Muenchen Muteins of α1m lipocalin and method of production therefor
US10526384B2 (en) 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
BR112015013515A2 (en) * 2012-12-10 2017-11-14 Hutchinson Fred Cancer Res methods of generating a mass-defined drug candidate library, and for identifying peptides having a pharmacological property
AU2014214037A1 (en) 2013-02-06 2015-07-02 Pieris Ag Novel lipocalin-mutein assays for measuring hepcidin concentration
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
KR20170004011A (en) 2014-05-22 2017-01-10 피어이스 파마슈티컬즈 게엠베하 Novel specific-binding polypeptides and uses thereof
EP3250586B1 (en) 2015-01-28 2021-10-27 Pieris Pharmaceuticals GmbH Novel proteins specific for angiogenesis
US11203753B2 (en) 2015-03-13 2021-12-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Hepcidin antagonists for use in the treatment of inflammation
CN114573680A (en) * 2015-05-04 2022-06-03 皮里斯制药有限公司 CD 137-specific proteins
CN107636014B (en) 2015-05-04 2021-12-07 皮里斯制药有限公司 Anti-cancer fusion polypeptides
PL3298030T3 (en) 2015-05-18 2023-05-08 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
JP6942060B2 (en) 2015-05-18 2021-09-29 ピエリス ファーマシューティカルズ ゲーエムベーハー Mutane of human lipocalin 2 with affinity for glypican-3 (GPC3)
EP3115066A1 (en) 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins
AU2016363668A1 (en) 2015-11-30 2018-05-24 Pieris Australia Pty Ltd. Novel anti-angiogenic fusion polypeptides
TW201725212A (en) 2015-12-10 2017-07-16 第一三共股份有限公司 Novel proteins specific for calcitonin gene-related peptide
WO2018234538A1 (en) 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism
CN107540746B (en) * 2017-10-17 2022-07-12 北京格根生物科技有限公司 Anti-vascular endothelial growth factor antibody and fusion protein with hepcidin
CN111542535A (en) * 2017-12-20 2020-08-14 圣安娜儿童癌症研究中心 Ligand-regulated protein-protein interaction systems
EP3946417A1 (en) 2019-03-29 2022-02-09 Pieris Pharmaceuticals GmbH Inhaled administration of lipocalin muteins
US20220023333A1 (en) * 2019-05-06 2022-01-27 Elena Valentinovna ARSHINTSEVA Method for increasing cancer patient's haemoglobin level
JP2023117892A (en) * 2022-02-14 2023-08-24 公益財団法人 鷹揚郷 hepcidin binding peptide

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (en) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk Production of normal human serum albumin a through gene recombination
FR2649991B2 (en) 1988-08-05 1994-03-04 Rhone Poulenc Sante USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
DK1087778T3 (en) 1998-06-08 2005-12-19 Hoffmann La Roche Use of PEG-IFN-alpha and ribavirin in the treatment of chronic hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (en) 1999-06-08 2001-01-11 Arne Skerra Muteins of the bilin binding protein
WO2002076489A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
AU2003264100A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
GB0504767D0 (en) * 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
JP2009509535A (en) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド Proteinaceous drugs and their use
CA2657307A1 (en) 2006-07-21 2008-01-24 Amgen Inc. Method of detecting and/or measuring hepcidin in a sample
ES2354653T3 (en) * 2006-08-01 2011-03-16 Pieris Ag LACRIMAL LIPOCALINE MUTEINS AND PROCEDURES TO OBTAIN THE SAME.
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
CN101372690A (en) * 2006-10-24 2009-02-25 汕头大学医学院 Human stomach cancer cell NGAL gene promoter region TPA core reaction element
TW201307390A (en) 2007-02-02 2013-02-16 Amgen Inc Hepcidin, hepcidin antagonists and methods of use
CL2008003190A1 (en) 2007-11-02 2009-09-04 Lilly Co Eli Antibody that selectively binds to mature human hepcidin-25; coding polynucleotide, vector and host cell comprising it; medical use to treat anemia, increase iron level, rediculocyte count, red cells, hemoglobin, or hematocrit; production process; pharmaceutical composition.
JP5701064B2 (en) 2008-01-25 2015-04-15 アムジエン・インコーポレーテツド Ferroportin antibody and method of use thereof
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP3381933B1 (en) * 2008-06-24 2020-06-03 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
PT2328931E (en) 2008-08-06 2013-11-07 Lilly Co Eli Anti-hepcidin-25 selective antibodies and uses thereof
RU2707126C2 (en) * 2009-12-07 2019-11-22 Пирис Аг Human lipolocal 2 malletes (lcn2, hngal) with affinity for specific target
WO2012022742A1 (en) * 2010-08-16 2012-02-23 Pieris Ag Binding proteins for hepcidin

Also Published As

Publication number Publication date
AU2011290751A1 (en) 2013-02-21
NZ606584A (en) 2014-10-31
WO2012022742A1 (en) 2012-02-23
CA2808392C (en) 2020-03-10
EP2606061A1 (en) 2013-06-26
KR101918024B1 (en) 2018-11-14
CA2808392A1 (en) 2012-02-23
KR20130103500A (en) 2013-09-23
ZA201300975B (en) 2014-06-25
EP2606061B1 (en) 2017-08-09
EP2606061B8 (en) 2017-09-27
CN103154023A (en) 2013-06-12
CN103154023B (en) 2017-04-05
KR20180088745A (en) 2018-08-06
US20170369542A1 (en) 2017-12-28
EP3299386A1 (en) 2018-03-28
US9051382B2 (en) 2015-06-09
AU2011290751B2 (en) 2015-08-13
US20150291675A1 (en) 2015-10-15
RU2625011C2 (en) 2017-07-11
US20130244955A1 (en) 2013-09-19
CN107082803A (en) 2017-08-22
DK2606061T3 (en) 2017-11-06
RU2013108919A (en) 2014-09-27
SG187695A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
IL271804A (en) Mice that make binding proteins
ZA201300975B (en) Binding proteins for hepcidin
SG10201401681PA (en) Novel antigen binding proteins
IL222980A0 (en) Il-1 binding proteins
ZA201304905B (en) TNF-a BINDING PROTEINS
EP2681239B8 (en) Antigen binding proteins
HK1202444A1 (en) Il-1 binding proteins il-1
EP2555797A4 (en) Tnf- binding proteins
HK1170506A1 (en) Bispecific antigen binding proteins
HK1199042A1 (en) Cd27l antigen binding proteins cd27l
ZA201205624B (en) Cd127 binding proteins
IL226157A0 (en) Antigen binding proteins
SG10201503080XA (en) Eif4e binding peptides
GB201418608D0 (en) Peridinin-chlorophyll binding proteins
GB201001596D0 (en) S100 protein binding interaction inhibitors
GB201003906D0 (en) Binding polypeptides
GB201103961D0 (en) Binding polypeptides